Analysis of Debt

Regeneron Pharmaceuticals Inc., balance sheet: debt

US$ in thousands

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Finance lease liabilities, current portion	—)	—)	—)	719,700)	—)
Long-term debt	1,984,400)	1,982,900)	1,981,400)	1,980,000)	1,978,500)
Finance lease liabilities, excluding current portion	720,000)	720,000)	720,000)	—)	717,200)
Total long-term debt and finance lease liabilities (carrying amount)	2,704,400)	2,702,900)	2,701,400)	2,699,700)	2,695,700)

Download chart

Debt item	Description	The company
Total long-term debt and finance lease liabilities (carrying amount)	Sum of the carrying values as of the balance sheet date of all debt plus capital lease obligations.	Regeneron Pharmaceuticals Inc. total debt increased from 2022 to 2023 and from 2023 to 2024.

	Dec 31, 2024
Selected Financial Data (US$ in thousands)
Long-term debt	1,484,000)
Finance lease liabilities	720,000)
Total long-term debt and finance lease liabilities (fair value)	2,204,000)
Financial Ratio
Debt, fair value to carrying amount ratio	0.81

Weighted-average interest rate on debt and finance lease liabilities: 2.91%

Interest rate	Debt amount¹	Interest rate × Debt amount
1.75%	1,243,300)	21,758)
2.80%	741,100)	20,751)
5.03%	720,000)	36,216)
Total	2,704,400)	78,725)
2.91%

¹ US$ in thousands

² Weighted-average interest rate = 100 × 78,725 ÷ 2,704,400 = 2.91%

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)